Skip to main content
. Author manuscript; available in PMC: 2019 Jul 29.
Published in final edited form as: Chin J Nat Med. 2017 Jun;15(6):401–416. doi: 10.1016/S1875-5364(17)30062-6

Table 1.

STs and DSTs in human clinical trials

Compounds Chemical Structures Clinical trial phase Disease Sponsor References
Mipsagargin (G-202) graphic file with name nihms-1041433-t0005.jpg Phase 1 Advanced solid tumors GenSpera, Inc. [43]
Phase 2 Chemotherapy-naive metastatic castrate-resistant prostate cancer GenSpera, Inc. [44]
A soluble prodrug of thapsigargin
DMAPT (or LC-1) graphic file with name nihms-1041433-t0006.jpg Phase 1 Acute myeloid leukemia Leuchemix Inc. [45]
A water-soluble analog of parthenolide
Artesunate graphic file with name nihms-1041433-t0007.jpg Phase 1 Hepatocellular carcinoma University Hospital, Ghent [46]
Phase 1 Solid tumors Georgetown University [47]
Phase 1 Cervical intraepithelial neoplasia grade 2/3, high-risk HPV (any strain) Sidney Kimmel
Comprehensive
Cancer Center		 [48]
Phase 2 Colorectal cancer, bowel cancer St George’s, University of London [49]
A semi-synthetic derivative of Artemisinin Phase 1 Metastatic breast cancer, locally advanced breast cancer Heidelberg University [50]
Artemether graphic file with name nihms-1041433-t0008.jpg Phase 1; Phase 2 Solid tumors LondonPharma Ltd. [51]
A semi-synthetic derivative of Artemisinin